XPhyto Therapeutics Corp.
15.12.2021 09:06:53 CET | ACCESS Newswire | Press release
VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / December 15, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on the development of its fast-dissolving CBD oral strips. With significant complexities involved in the planning and preparation for the pending human pilot study, the Company is pleased to announce that its European human CBD bioavailability study will commence in January 2022.
Prof. Dr. Beckert said, "the clinical trial of our CBD product is aiming to demonstrate the efficient and precise dosing of the treatment. If successful, this could make a significant difference to Epilepsy patients and we are excited to commence the trial next year."
XPhyto is developing a hybrid-generic CBD prescription drug formulation that employs the Company's proprietary oral dissolvable ("ODF") platform to deliver precise and efficient CBD dosages for the treatment of certain forms of childhood Epilepsy.
The US Food & Drug Administration (FDA) and European Medicines Agency (EMA) have approved CBD based medical products from other companies for the treatment of severe childhood forms of Epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome. The currently approved and registered formulation of CBD is a lipophilic solution in sesame oil with a standard dosage of 750 mg/day. Due to low bioavailability (approximately 5%) the formulation could be considered highly inefficient compared to the XPhyto ODF platform.
For the purpose of carrying out XPhyto's clinical study, the following important and necessary items have been completed or received: Product Development Report, Investigational Medicinal Product Dossier, Permit for Clinical Study, manufacture of clinical product samples; Product Specification File; monitoring agreement; and Import Authorization to the location of the FDA-inspected Clinical Research Center. Pending success in the CBD pilot study, the Company expects to carry out a pivotal clinical study in 2H of 2022.
The Company's CBD-based Epilepsy treatment program is one of several dissolvable oral drug delivery programs. Oral thin film drug delivery is a large and growing international industry which provides an alternative to conventional solid and liquid oral dosage forms. Transparency Market Research estimates that the global market for thin film drug manufacturing will be worth US$15.98 billion by 2024, rising at a 9.0% CAGR between 2019 and 2024. XPhyto's additional oral thin film drug delivery programs include both cannabinoid and non-cannabinoid products for pain, neurology, and infectious disease. The Cannabidiol Market revenue is estimated to be worth over US$89 billion by 2026 according to Global Market Insights Inc.
Executive management of XPhyto's drug formulation business is led by Prof. Dr. Beckert, managing director of Vektor Pharma TF GmbH. Prof Dr. Beckert is a German-based scientist and experienced corporate executive who is leading XPhyto's drug formulation and diagnostics operations.
About XPhyto Therapeutics Corp.
XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
XPhyto Therapeutics Corp.
Hugh Rogers, CEO and Director
Investor Inquiries:
Mr. Knox Henderson
T: 604-551-2360
E: info@xphyto.com
Forward looking statements
This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "develop", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "potential", "propose" and other similar words, or statements that certain events or conditions "may" or "will" occur, and in this release include the statement regarding the Company's goal of building a successful diagnostic, drug delivery, and medical cannabis company. Forward-looking statements are only predictions based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not succeed in developing a commercial product; that the sale of products may not be a viable business; that the Company may be unable to scale its business; product liability risks; product regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; currency risks; competition; international risks; and other risks beyond the Company's control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.
SOURCE: XPhyto Therapeutics Corp.
View source version on accesswire.com:
https://www.accesswire.com/677717/XPhyto-Epilepsy-Clinical-Trial-Planned-in-2022-with-Its-Proprietary-Fast-Dissolving-CBD-Oral-Strips
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AP Technologies Acquires Blueacre Technology, Adding Nitinol and Precision Laser Processing to Its Catheter Platform19.5.2026 16:00:00 CEST | Press release
Acquisition extends AP Technologies' vertically integrated catheter platform into nitinol and precision laser processing. Dundalk, Ireland joins the company's network of Centers of Excellence as its first European operation. SINGAPORE AND DUNDALK, IRELAND / ACCESS Newswire / May 19, 2026 / AP Technologies, a vertically integrated contract manufacturer of catheters and medical tubing, today announced the acquisition of Blueacre Technology, a Dundalk, Ireland specialist in laser micromachining and nitinol processing for the medical device industry. The acquisition establishes AP Technologies' first European operation in Ireland's medtech corridor, and extends its catheter platform into the laser-processed metallic components used in next-generation minimally invasive devices. Terms were not disclosed. Blueacre brings nearly two decades of capability in laser micromachining and nitinol processing for the medical device industry, including femtosecond and picosecond laser cutting, laser we
Business Leaders Still Primarily Use AI for Simple Tasks, Study from General Assembly and EZRA Finds19.5.2026 15:00:00 CEST | Press release
Those who have received leadership-specific AI training more likely to use AI more often and more strategically NEW YORK CITY, NY / ACCESS Newswire / May 19, 2026 / A new survey of more than 500 U.S. and U.K. business leaders found that while they are increasingly confident in their own AI skills, the most common use cases of the technology at the leadership level remain simple tasks like searching for information (69%), summarizing documents (68%) and drafting emails (58%). Strategic applications such as scenario planning (27%), organizational design (27%) and financial modeling (28%) lag far behind. The research was conducted by General Assembly, a global leader in practical AI skills training, in collaboration with EZRA, a leading global coaching and learning provider, both LHH brands. The study also surfaces a sharp divide between leadership levels. Vice presidents consistently fall behind director-level colleagues across nearly every measure of AI adoption and competence, emerging
Europe's Hospital Cybersecurity Hot Zones and Top Cyber Vendors as EHR and EPR Attacks Shift From Data Theft to Care Disruption19.5.2026 14:50:00 CEST | Press release
Recent European hospital incidents, NIS2 accountability, EPR exposure, supplier concentration, and 72-hour downtime weakness are pushing buyers toward clinical-continuity cybersecurity ahead of HIMSS26 Europe COPENHAGEN, DK / ACCESS Newswire / May 19, 2026 / Black Book Research today issued a new European hospital cybersecurity advisory identifying the countries, attack surfaces, vendor categories, and evaluation standards now shaping hospital cybersecurity buying decisions across Europe. The advisory builds on Black Book's Pre-HIMSS26 Europe Copenhagen Cybersecurity Demand Pulse Survey of 284 self-identified European hospital, health system, HIT, clinical-digital, cybersecurity, procurement, risk, and executive respondents seeking cybersecurity options around HIMSS26 Europe in Copenhagen. Black Book reports that European hospital cybersecurity has moved beyond breach response. The 2026 priority is now clinical availability: protecting EHRs, EPRs, identity systems, lab platforms, pharm
AI Trading Bots Revolutionise Stock, Gold, and Forex Trading: Funds Coin Leads the Move with Guaranteed Profit Option Strategy19.5.2026 14:00:00 CEST | Press release
DENVER, CO / ACCESS Newswire / May 19, 2026 / Forex has always been the world's largest digital financial market in 2026. Now it has become entirely a 24-hour, data-saturated environment. According to the Bank for International Settlements, global OTC foreign exchange turnover reached $9.6 trillion per day in April 2025. This means the foreign exchange turnover was up 28% from 2022. This is a figure that underscores just how deeply connected forex is to global liquidity, risk management, and capital flows. Inside that volume, the competition has intensified dramatically. In 2026, retail traders are no longer competing mainly against other individuals; they are competing against automated systems, and AI-assisted execution engines like Funds Coin. The platform operates across stocks, forex, and financial markets simultaneously. Manual trading, in this environment, is not just inefficient. It is structurally outpaced. Why AI Bots Are Taking Over Forex The following table is provided for
Northfield's Flagship Investment Juno Corp. Discovers Heavy Rare Earth Magnet Metals at Vespa19.5.2026 13:01:00 CEST | Press release
Broadens Juno's Polymetallic Critical Minerals System in Ontario's Ring of Fire TORONTO, ON / ACCESS Newswire / May 19, 2026 / Northfield Capital Corporation ("Northfield" or the "Company") (TSXV:NFD.A) is pleased to comment on the announcement made today by Juno Corp. ("Juno") regarding the discovery of heavy rare earth element ("HREE") mineralization, including the magnet metals neodymium, praseodymium, dysprosium and terbium, within Juno's Vespa critical minerals system in Ontario's Ring of Fire (the "Juno Announcement"). For the full text of the Juno Announcement, including the technical disclosure relating to drill hole VES-26-025 and the associated assay results, please refer to Juno's press release dated May 19, 2026, available at www.junocorp.com. Northfield holds an approximately 35% equity interest in Juno, making Juno one of the most significant investments in Northfield's portfolio. The discovery disclosed in the Juno Announcement broadens the polymetallic critical minerals
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom